Patients with Philadelphia-Positive Leukemia with BCR-ABL Kinase Mutations before Allogeneic Transplantation Predominantly Relapse with the Same Mutation

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 1, 2015, Pages 184-189

[No Author Info available]

Author keywords

Allogeneic hematopoietic stem cell transplantation; BCR ABL kinase mutations; Chronic myeloid leukemia; Philadelphia chromosome acute lymphoblastic leukemia

Indexed keywords

ABELSON KINASE; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; PROTEIN KINASE INHIBITOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER RECURRENCE; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PHILADELPHIA 1 CHROMOSOME; PHILADELPHIA CHROMOSOME POSITIVE CELL; POLYMERASE CHAIN REACTION; WILD TYPE; ADOLESCENT; ALLOTRANSPLANTATION; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; MORTALITY; MUTATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENT DISEASE; RETROSPECTIVE STUDY; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; UNRELATED DONORS;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; FEMALE; FUSION PROTEINS, BCR-ABL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MUTATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; UNRELATED DONORS;

EID: 84927127674     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.09.012     Document Type: Article

References (39)

1. Jabbour E., Kantarjian H., Jones D., et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 2006, 20:1767-1773.
2. Lahaye T., Riehm B., Berger U., et al. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: A 4.5-year follow-up. Cancer 2005, 103:1659-1669.
3. Soverini S., Vitale A., Poerio A., et al. Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis. Haematologica 2011, 96:552-557.
4. Hochhaus A., Kreil S., Corbin A.S., et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002, 16:2190-2196.
5. Gratwohl A., Brand R., Apperley J., et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006, 91:513-521.
6. Barrett A.J., Horowitz M.M., Ash R.C., et al. Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1992, 79:3067-3070.
7. Copelan E.A., Crilley P.A., Szer J., et al. Late mortality and relapse following BuCy2 and HLA-identical sibling marrow transplantation for chronic myelogenous leukemia. Biol Blood Marrow Transplant 2009, 15:851-855.
8. Kantarjian H.M., O'Brien S., Cortes J.E., et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2002, 100:1590-1595.
9. Olavarria E., Ottmann O.G., Deininger M., et al. Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia 2003, 17:1707-1712.
10. DeAngelo D.J., Hochberg E.P., Alyea E.P., et al. Extended follow-up of patients treated with imatinib mesylate (Gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. Clin Cancer Res 2004, 10:5065-5071.
11. Hess G., Bunjes D., Siegert W., et al. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study. JClin Oncol 2005, 23:7583-7593.
12. Palandri F., Amabile M., Rosti G., et al. Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis. Bone Marrow Transplant 2007, 39:189-191.
13. Atallah E., Kantarjian H., De Lima M., et al. The role of dasatinib in patients with Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML) relapsing after stem cell transplantation (SCT). Blood (ASH Annual Meeting Abstracts) 2006, 108. Abstract 4520.
14. Klyuchnikov E., Schafhausen P., Kroger N., et al. Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia. Acta Haematol 2009, 122:6-10.
15. Wright M.P., Shepherd J.D., Barnett M.F., et al. Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2010, 16:639-646.
16. Olavarria E., Siddique S., Griffiths M.J., et al. Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. Blood 2007, 110:4614-4617.
17. Carpenter P.A., Snyder D.S., Flowers M.E., et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 2007, 109:2791-2793.
18. Wassmann B., Pfeifer H., Stadler M., et al. Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2005, 106:458-463.
19. Pfeifer H., Wassmann B., Bethge W. Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia. Leukemia 2013, 27:1254-1262.
20. Ram R., Storb R., Sandmaier B.M., et al. Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia. Haematologica 2011, 96:1113-1120.
21. Anderlini P., Sheth S., Hicks K., et al. Re: Imatinib mesylate administration in the first 100 days after stem cell transplantation. Biol Blood Marrow Transplant 2004, 10:883-884.
22. Kang B.W., Moon J.H., Chae Y.S., et al. Pre-emptive treatment with nilotinib after second allogeneic transplantation in a Philadelphia chromosome-positive acute lymphoblastic leukemia patient with high risk of relapse. Acta Haematol 2010, 123:242-247.
23. Merante S., Colombo A.A., Calatroni S., et al. Nilotinib restores long-term full-donor chimerism in Ph-positive acute lymphoblastic leukemia relapsed after allogeneic transplantation. Bone Marrow Transplant 2009, 44:263-264.
24. Tiribelli M., Sperotto A., Candoni A., et al. Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib. Leuk Res 2009, 33:174-177.
25. Czyz A., Lewandowski K., Kroll R., Komarnicki M. Dasatinib-induced complete molecular response after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to prior imatinib-containing regimen: a case report and discussion. Med Oncol 2010, 27:1123-1126.
26. Caocci G., Vacca A., Ledda A., et al. Prophylactic and preemptive therapy with dasatinib after hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2012, 18:652-654.
27. Tichelli A., Bucher C., Rovo A., et al. Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. Blood 2007, 110:3463-3471.
28. Kang H.Y., Hwang J.Y., Kim S.H., et al. Comparison of allele specific oligonucleotide-polymerase chain reaction and direct sequencing for high throughput screening of ABL kinase domain mutations in chronic myeloid leukemia resistant to imatinib. Haematologica 2006, 91:659-662.
29. Hughes T., Saglio G., Branford S., et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. JClin Oncol 2009, 27:4204-4210.
30. Redaelli S., Piazza R., Rostagno R., et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. JClin Oncol 2009, 27:469-471.
31. Soverini S., De Benedittis C., Papayannidis C. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: the main changes are in the type of mutations, but not in the frequency of mutation involvement. Cancer 2014, 120:1002-1009.
32. Gruber F.X., Hjorth-Hansen H., Mikkola1 I., et al. Anovel BCR-ABL splice isoform is associated with the L248V mutation in CML patients with acquired resistance to imatinib. Leukemia 2006, 20:2057-2060.
33. Pfeifer H., Wassmann B., Pavlova A., et al. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2007, 110:727-734.
34. Jabbour E., Cortes J., Santos F.P., et al. Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood 2007, 117:3641-3647.
35. Jones D., Thomas D., Yin C.C., et al. Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. Cancer 2008, 113:985-994.
36. Hanfstein B., Muller M.C., Kriel S., et al. Dynamics of mutation BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy. Haematologica 2011, 96:360-366.
37. Branford S., Rudski Z., Walsh S., et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2012, 102:276-283.
38. Khorashad J.S., Kelley T.W., Szankasi P., et al. BCR-ABL1 compound mutation in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood 2013, 121:489-498.
39. Soverini S., De Benedittis C., Polakova K.M., et al. Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. Blood 2013, 122:1634-1648.